AKESO Jumps as AstraZeneca's $2B Strategic Investment in Summit Provides Top-Tier Pharma Endorsement for Ivonescimab

Market Focus

Yesterday

On September 29, AKESO rose 10% in regular trading. The surge was driven by AstraZeneca's announcement of a $2 billion strategic investment in Summit Therapeutics through a preferred stock subscription at $18.36 per share equivalent, representing an 18.6% premium over Summit's closing price.

The core asset underlying this transaction is ivonescimab, the world's first PD-1/VEGF bispecific antibody developed by AKESO, which was out-licensed to Summit for a potential total deal value of up to $5 billion. The market widely views this as a significant endorsement of ivonescimab's global commercial potential by a top multinational pharmaceutical company. Earlier in September, ivonescimab demonstrated a statistically significant overall survival benefit in the Phase 3 HARMONi-2 trial, with a median OS of 30.8 months versus 22.6 months for pembrolizumab in first-line PD-L1-positive NSCLC. Multiple international investment banks maintain Buy ratings, with CICC raising its target price to HK$130 and Jefferies maintaining a target of HK$226.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1160176634"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1160176634\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1160176634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160176634","market":"hk","top_or_hot":-1,"title":"AKESO Jumps as AstraZeneca's $2B Strategic Investment in Summit Provides Top-Tier Pharma Endorsement for Ivonescimab","media":"Market Focus","content":"<html><head></head><body><p style=\"text-align: left;\">On September 29, AKESO rose 10% in regular trading. The surge was driven by AstraZeneca&#39;s announcement of a $2 billion strategic investment in Summit Therapeutics through a preferred stock subscription at $18.36 per share equivalent, representing an 18.6% premium over Summit&#39;s closing price.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/d4f935b852bb22406d2c4752b1339790\" title=\"\" tg-width=\"442\" tg-height=\"107\"/></p><p style=\"text-align: left;\">The core asset underlying this transaction is ivonescimab, the world&#39;s first PD-1/VEGF bispecific antibody developed by AKESO, which was out-licensed to Summit for a potential total deal value of up to $5 billion. The market widely views this as a significant endorsement of ivonescimab&#39;s global commercial potential by a top multinational pharmaceutical company. Earlier in September, ivonescimab demonstrated a statistically significant overall survival benefit in the Phase 3 HARMONi-2 trial, with a median OS of 30.8 months versus 22.6 months for pembrolizumab in first-line PD-L1-positive NSCLC. Multiple international investment banks maintain Buy ratings, with CICC raising its target price to HK$130 and Jefferies maintaining a target of HK$226.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AKESO Jumps as AstraZeneca's $2B Strategic Investment in Summit Provides Top-Tier Pharma Endorsement for Ivonescimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAKESO Jumps as AstraZeneca's $2B Strategic Investment in Summit Provides Top-Tier Pharma Endorsement for Ivonescimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-29 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: left;\">On September 29, AKESO rose 10% in regular trading. The surge was driven by AstraZeneca&#39;s announcement of a $2 billion strategic investment in Summit Therapeutics through a preferred stock subscription at $18.36 per share equivalent, representing an 18.6% premium over Summit&#39;s closing price.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/d4f935b852bb22406d2c4752b1339790\" title=\"\" tg-width=\"442\" tg-height=\"107\"/></p><p style=\"text-align: left;\">The core asset underlying this transaction is ivonescimab, the world&#39;s first PD-1/VEGF bispecific antibody developed by AKESO, which was out-licensed to Summit for a potential total deal value of up to $5 billion. The market widely views this as a significant endorsement of ivonescimab&#39;s global commercial potential by a top multinational pharmaceutical company. Earlier in September, ivonescimab demonstrated a statistically significant overall survival benefit in the Phase 3 HARMONi-2 trial, with a median OS of 30.8 months versus 22.6 months for pembrolizumab in first-line PD-L1-positive NSCLC. Multiple international investment banks maintain Buy ratings, with CICC raising its target price to HK$130 and Jefferies maintaining a target of HK$226.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1160176634","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160176634","pubTimestamp":1790645469,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 29, AKESO rose 11.09% in regular trading, trading at HK$102.5/share, with turnover of HK$273 million. The surge was driven by AstraZeneca's announcement of a $2 billion strategic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"阿斯利康对 Summit 的 20 亿美元战略投资为 Ivonescimab 提供顶级制药代言，AKESO 股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/b1faebf60c6bd8b6f77b03e83b91a916","symbols_score_info":{"09926":1},"content_text":"On September 29, AKESO rose 10% in regular trading. The surge was driven by AstraZeneca's announcement of a $2 billion strategic investment in Summit Therapeutics through a preferred stock subscription at $18.36 per share equivalent, representing an 18.6% premium over Summit's closing price.The core asset underlying this transaction is ivonescimab, the world's first PD-1/VEGF bispecific antibody developed by AKESO, which was out-licensed to Summit for a potential total deal value of up to $5 billion. The market widely views this as a significant endorsement of ivonescimab's global commercial potential by a top multinational pharmaceutical company. Earlier in September, ivonescimab demonstrated a statistically significant overall survival benefit in the Phase 3 HARMONi-2 trial, with a median OS of 30.8 months versus 22.6 months for pembrolizumab in first-line PD-L1-positive NSCLC. Multiple international investment banks maintain Buy ratings, with CICC raising its target price to HK$130 and Jefferies maintaining a target of HK$226.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}